Latigo Biotherapeutics, Inc. SEC filings LTGO

Latigo Biotherapeutics, Inc. has 43 filings in SEC EDGAR's recent list, going back to Feb 13, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations, officer or director change). The company's fiscal year ends on December 31.

Latigo Biotherapeutics, Inc. SEC filings
Form Description Filed Period
10-Q Quarterly report Nov 5, 2026 Sep 30, 2026
8-K Current report
Results of operations, Officer or director change
Nov 5, 2026 Nov 3, 2026
10-Q Quarterly report Sep 3, 2026 Jun 30, 2026
8-K Current report
Results of operations
Sep 3, 2026 Sep 3, 2026
S-8 Employee stock plan registration Aug 10, 2026 —
8-K Current report
Bylaw or fiscal year change, Other events
Aug 10, 2026 Aug 10, 2026
424B4 Prospectus Aug 7, 2026 —
EFFECT Filing Aug 6, 2026 —
S-1MEF Filing Aug 6, 2026 —
CERT Filing Aug 6, 2026 —
8-A12B Filing Aug 4, 2026 —
S-1/A Amended registration statement Aug 4, 2026 —
S-1/A Amended registration statement Aug 3, 2026 —
S-1 Registration statement Jul 17, 2026 —
DRS/A Filing Jun 5, 2026 —
DRS/A Filing May 18, 2026 —
DRS Filing Mar 27, 2026 —
D Filing Feb 13, 2025 —

Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
LTGO (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Thousand Oaks, CA
SEC filer status
, Emerging growth company
SEC CIK
2056611

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.